

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

HALOZYME THERAPEUTICS INC  
Form SC 13G/A  
February 14, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13GA  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO  
FILED PURSUANT TO 13d-2  
( Amendment   1   ) \*

HALOZYME THERAPEUTICS, INC.  
(Name of Issuer)

COMMON STOCK, \$0.01 PAR VALUE  
(Title of Class of Securities)

40637H 10 9

-----  
(CUSIP Number)

David Ramsay, 11588 Sorento Valley Road  
San Diego, California 92121  
(858) 794-8889

-----  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

December 31, 2004

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule  
is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities, and  
for any subsequent amendment containing information which would alter  
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed  
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of  
1934 ("Act") or otherwise subject to the liabilities of that section of the Act  
but shall be subject to all other provisions of the Act (however, see the  
Notes).

SCHEDULE 13G  
-----

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 40637H 10 9

Page 2 of 6 Pages

1 NAME OF REPORTING PERSON  
SS. OR I.R.S IDENTIFICATION NO. OF ABOVE PERSON

Jonathan Spanier

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) [ ]  
(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5 NUMBER OF SOLE VOTING POWER  
SHARES 2,770,270

6 BENEFICIALLY OWNED BY SHARED VOTING POWER  
EACH REPORTING N/A

7 PERSON SOLE DISPOSITIVE POWER  
WITH 2,770,270

8 SHARED DISPOSITIVE POWER  
N/A

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,770,270

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.81%

12 TYPE OF REPORTING PERSON

IN

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

SCHEDULE 13G

40637H 10 9

Page 3 of 6 Pages

ITEM 1(a). NAME OF ISSUER:

Hyalozyme Therapeutics, Inc.

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

11588 Sorento Valley Rd.  
San Diego, California 92121

ITEM 2(a). NAME OF PERSON FILING:

The Person filing this is Jonathan Spanier

ITEM 2(b). ADDRESS OF PRINCIPAL OFFICES OR, IF NONE, RESIDENCE:

8732 St. Ives Drive, Los Angeles, California 90069

ITEM 2(c). CITIZENSHIP:

United States

ITEM 2(d). TITLE OF CLASS OF SECURITIES:

Common Stock

ITEM 2(e). CUSIP NUMBER: 40637H 10 9

SCHEDULE 13G

CUSIP No. 40637H 10 9

Page 4 of 6 Pages

ITEM 3. IF THE STATEMENT IS BEING FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE FILING PERSON IS A:

- (a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with 13d-1(b)(I)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with 13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

- 13d-1(b) (1) (ii) (G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
- (i)  A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with 13d-1(b) (1) (ii) (J).

If this statement is filed pursuant to 13d-1(c), check this box.

ITEM 4. OWNERSHIP:

The information in Items 5-11 on the cover page (page 2) of this Schedule 13G is incorporated by reference.

Includes 1,360,257 shares and 655,219 warrants to purchase shares, 474,890 shares and 211,570 warrants to purchase shares held by Jonathan Spanier IRA Account, includes 50,000 shares held by Jonathan Spanier under a custodial accounts for the benefit of a minor. Also includes 11,667 shares and 6,667 warrants to purchase share held by Grove Capital, LLC in which Jonathan Spanier is a member. Each of Jonathan Spanier and the Jonathan Spanier IRA Account may be deemed beneficial owners of the shares held by Grove Capital, LLC however, each disclaims beneficial ownership except to the extent of their pecuniary interest therein.

SCHEDULE 13G

-----  
CUSIP No. 40637H 10 9  
-----

-----  
Page 5 of 6 Pages  
-----

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than five percent of the class of securities, check the following

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not Applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Not Applicable.

ITEM 10. CERTIFICATION.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SCHEDULE 13G

-----  
CUSIP No. 40637H 10 9  
-----

-----  
Page 6 of 6 Pages  
-----

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2005

By: /s/ Jonathan Spanier  
-----

Jonathan Spanier

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

ATTENTION. INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).